Sera Prognostics (NASDAQ:SERA) Lifted to Hold at Zacks Investment Research

Sera Prognostics (NASDAQ:SERAGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports.

According to Zacks, “Sera Prognostics Inc. is a women’s health diagnostics company. It focused on improving maternal and neonatal health by providing pregnancy biomarker information to doctors and patients. Sera Prognostics Inc. is based in SALT LAKE CITY. “

A number of other analysts have also commented on SERA. Citigroup lowered Sera Prognostics from a “buy” rating to a “neutral” rating in a report on Wednesday, March 30th. Berenberg Bank initiated coverage on Sera Prognostics in a research note on Wednesday, April 27th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Sera Prognostics has an average rating of “Buy” and a consensus target price of $18.50.

Shares of Sera Prognostics stock opened at $1.52 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 15.77 and a quick ratio of 15.76. The business has a 50-day simple moving average of $2.50 and a 200 day simple moving average of $5.82. The firm has a market capitalization of $46.96 million and a price-to-earnings ratio of -0.35. Sera Prognostics has a one year low of $1.43 and a one year high of $15.50.

Sera Prognostics (NASDAQ:SERAGet Rating) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.08 million. Sera Prognostics had a negative return on equity of 58.37% and a negative net margin of 38,185.05%. On average, sell-side analysts expect that Sera Prognostics will post -1.5 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Sanders Morris Harris LLC lifted its stake in Sera Prognostics by 0.4% in the fourth quarter. Sanders Morris Harris LLC now owns 574,280 shares of the company’s stock valued at $3,945,000 after purchasing an additional 2,046 shares during the last quarter. American International Group Inc. purchased a new position in Sera Prognostics in the third quarter valued at approximately $29,000. Deutsche Bank AG purchased a new position in Sera Prognostics in the third quarter valued at approximately $30,000. Bank of America Corp DE lifted its stake in Sera Prognostics by 768.8% in the fourth quarter. Bank of America Corp DE now owns 3,597 shares of the company’s stock valued at $25,000 after purchasing an additional 3,183 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in Sera Prognostics by 4.9% in the first quarter. BlackRock Inc. now owns 186,140 shares of the company’s stock valued at $707,000 after purchasing an additional 8,718 shares during the last quarter. Hedge funds and other institutional investors own 63.20% of the company’s stock.

About Sera Prognostics (Get Rating)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.

Featured Stories

Get a free copy of the Zacks research report on Sera Prognostics (SERA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.